



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




Raloxifene 4'-Glucuronide

Item No. 27831

CAS Registry No.: 182507-22-8
Formal Name: 4-[6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]benzoyl]benzo[b]thien-2-yl]phenyl, β -D-glucopyranosiduronic acid

Synonym: Ral-4'-Gluc
MF: C₃₄H₃₅NO₁₀S
FW: 649.7
Purity: \geq 95%
Supplied as: A solid
Storage: -20°C
Stability: \geq 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Raloxifene 4'-glucuronide is supplied as a solid. A stock solution may be made by dissolving the raloxifene 4'-glucuronide in the solvent of choice, which should be purged with an inert gas. Raloxifene 4'-glucuronide is slightly soluble in methanol and DMSO.

Description

Raloxifene 4'-glucuronide is a metabolite of the selective estrogen receptor modulator raloxifene (Item No. 10011620).¹ It is formed from raloxifene via the UDP-glucuronosyltransferase (UGT) isoforms UGT1A1, UGT1A8, and UGT1A10.² It binds to the estrogen receptor with an IC₅₀ value of 370 nM.¹ Raloxifene 4'-glucuronide inhibits the voltage-gated potassium channel K_v4.3 by 6.2 and 20.1% when used at concentrations of 10 and 30 μ M, respectively.³

References

1. Sun, D., Jones, N.R., Manni, A., *et al.* Characterization of raloxifene glucuronidation: Potential role of UGT1A8 genotype on raloxifene metabolism *in vivo*. *Cancer Prev. Res. (Phila)*. **6(7)**, 719-730 (2013).
2. Kemp, D.C., Fan, P.W., and Stevens, J.C. Characterization of raloxifene glucuronidation *in vitro*: Contribution of intestinal metabolism to presystemic clearance. *Drug Metab. Dispos.* **30(6)**, 694-700 (2002).
3. Chae, Y.J., Kim, D.H., Lee, H.J., *et al.* Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner. *Pflugers Arch.* **467(8)**, 1663-1676 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/19/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM